These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 729645)

  • 21. Properties of dopamine efflux from rat striatal tissue caused by amphetamine and p-hydroxyamphetamine.
    Fischer JF; Cho AK
    Proc West Pharmacol Soc; 1976; 19():179-82. PubMed ID: 995984
    [No Abstract]   [Full Text] [Related]  

  • 22. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system.
    Javoy F; Sotelo C; Herbet A; Agid Y
    Brain Res; 1976 Feb; 102(2):201-15. PubMed ID: 1247882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotyped behavior and hyperthermia in dogs: correlation with the levels of amphetamine and p-hydroxyamphetamine in plasma and CSF.
    Bareggi SR; Gomeni R; Becker RE
    Psychopharmacology (Berl); 1978 Jun; 58(1):89-94. PubMed ID: 97724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra.
    Robinson TE; Noordhoorn M; Chan EM; Mocsary Z; Camp DM; Whishaw IQ
    Synapse; 1994 May; 17(1):16-25. PubMed ID: 8042143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems.
    Matsuda LA; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1989 Dec; 251(3):901-8. PubMed ID: 2600821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.
    Fischer JF; Cho AK
    J Pharmacol Exp Ther; 1979 Feb; 208(2):203-9. PubMed ID: 762652
    [No Abstract]   [Full Text] [Related]  

  • 28. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary excretion of amphetamine and 4'-hydroxyamphetamine by Sprague Dawley and dark Agouti rats.
    Law MY; Moody DE
    Life Sci; 1994; 54(15):1073-9. PubMed ID: 8152328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective accumulation of hydroxylated metabolites of amphetamine in rat striatum and hypothalamus.
    Dougan DF; Duffield AM; Duffield PH; Wade DN
    Br J Pharmacol; 1986 May; 88(1):285-90. PubMed ID: 3708221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axonal transport of proteins and glycoproteins in the rat nigro-striatal pathway and the effects of 6-hydroxydopamine.
    Roger LJ; Breese GR; Morell P
    Brain Res; 1980 Sep; 197(1):95-112. PubMed ID: 6156743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and D-amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats.
    Kish LJ; Palmer MR; Gerhardt GA
    Brain Res; 1999 Jun; 833(1):58-70. PubMed ID: 10375677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors.
    Yokoyama C; Okamura H
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1016-30. PubMed ID: 9023319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine.
    Spooren WP; Waldmeier P; Gentsch C
    J Neural Transm (Vienna); 1999; 106(9-10):825-33. PubMed ID: 10599865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of amphetamine and its hydroxylated metabolites in various areas of the rat brain.
    Jori A; Caccia S
    J Pharm Pharmacol; 1974 Sep; 26(9):746-8. PubMed ID: 4155759
    [No Abstract]   [Full Text] [Related]  

  • 37. Neurotoxic action of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with D-amphetamine.
    Nowak P; Kostrzewa RM; Kwieciński A; Bortel A; Labus Ł; Brus R
    J Physiol Pharmacol; 2005 Jun; 56(2):325-33. PubMed ID: 15985712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.
    Costall B; Marsden CD; Naylor RJ; Pycock CJ
    Brain Res; 1976 Dec; 118(1):87-113. PubMed ID: 990957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A continuous striatal infusion of 6-hydroxydopamine produces a terminal axotomy and delayed behavioral effects.
    Jones BE; Boylan CB; Fritsche M; Juhasz M; Jackson C; Wiegand SJ; Hyman C; Lindsay RM; Altar CA
    Brain Res; 1996 Feb; 709(2):275-84. PubMed ID: 8833764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.